Bayer claims Abbott’s Humira infringes its patent
Bayer filed suit against Abbott Dec. 24 alleging that Humira (adalimumab) infringes its patent covering a composition of human monoclonal antibodies which bind to human tumor necrosis factor alpha. Bayer said the patent, No. 5,654,407, which was issued in 1997, does not cover a specific Bayer drug. Humira, a blockbuster autoimmune therapy, had worldwide sales of $3.1 billion in 2007 and is projected to generate $4.4 billion in sales for 2008 (1"The Pink Sheet," Oct. 20, 2008, p. 5). The complaint, filed in the U.S. District Court for the Eastern District of Texas, requests a jury trial and a finding of willful infringement. Abbott said Humira does not infringe Bayer's patent and that it believes the patent is invalid
You may also be interested in...
Sales of Abbott's multi-faceted biologic Humira seem to be going from strength to strength, unencumbered by the economic turmoil even though it's an expensive biologic in highly competitive markets
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.